FDA Approves Margenza Plus Chemo for Pretreated HER2+ MBC

Options
Moderators
Moderators Member Posts: 25,912
edited December 2020 in Stage IV/Metastatic Breast Cancer, Open to All To Contribute

FDA Approves Margenza Plus Chemotherapy for Pretreated Metastatic HER2-Positive Breast Cancer
December 17, 2020
On Dec. 16, 2020, the FDA approved the targeted therapy Margenza in combination with chemotherapy to treat people diagnosed with metastatic HER2-positive breast cancer who have been treated previously with two or more anti-HER2 regimens, at least one of which was for metastatic disease. Read more...

· Share on FacebookShare on Twitter

Categories